[Sulfasalazine in the treatment of ankylosing spondylitis].

Ninety-five patients with ankylosing spondylitis received either sulphasalazine (less than or equal to 3 g/day) or placebo for 24 weeks. The patients who received sulphasalazine showed significantly improved clinical parameters [duration of morning stiffness (p less than 0.05), the number of painful and swollen joints (less than 0.05)] and laboratory parameters [erythrocyte sedimentation rate (p less than 0.001), haptoglobin (p less than 0.05), IgG (p less than 0.05), IgA (p less than 0.001), IgM (p less than 0.05)]. No statistically significant differences were seen in the patients receiving placebo. The results suggest that sulphasalazine is effective for the treatment of patients with ankylosing spondylitis. In these patients, there was also a diminution of the daily dosage of nonsteroidal antiinflammatory drugs. In the majority of patients, clinical and laboratory improvements were expressed more pronouncedly in the peripheral form of ankylosing spondylitis than in the axial form, but statistically no significant differences were found between the two groups.
AuthorsI Krajnc
JournalLijec̆nic̆ki vjesnik (Lijec Vjesn) 1990 May-Jun Vol. 112 Issue 5-6 Pg. 171-4 ISSN: 0024-3477 [Print] YUGOSLAVIA
Vernacular TitleSulfasalazin u lijecenju ankilozirajućeg spondilitisa.
PMID1978212 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article)
Chemical References
  • Sulfasalazine
  • Adult
  • Female
  • Humans
  • Male
  • Spondylitis, Ankylosing (drug therapy)
  • Sulfasalazine (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: